ArticleJournal for immunotherapy of cancer2022

CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling.

Samantha M Fix et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.